Journal
Cancer immunology, immunotherapy
Publication Date
10-1-2023
Volume
72
Issue
10
First Page
3323
Last Page
3335
Document Type
Open Access Publication
DOI
10.1007/s00262-023-03492-6
Rights and Permissions
de Jonge, P.K.J.D., van Hauten, P.M.M., Janssen, L.D. et al. Good manufacturing practice production of CD34+ progenitor-derived NK cells for adoptive immunotherapy in acute myeloid leukemia. Cancer Immunol Immunother 72, 3323–3335 (2023). https://doi.org/10.1007/s00262-023-03492-6. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Recommended Citation
de Jonge, P K J D; van Hauten, P M M; Janssen, L D; de Goede, A L; Berrien-Elliott, M M; van der Meer, J M R; Mousset, C M; Roeven, M W H; Foster, M; Blijlevens, N; Hobo, W; Fehniger, T A; Jansen, J H; Schaap, N P M; and Dolstra, H, "Good manufacturing practice production of CD34+ progenitor-derived NK cells for adoptive immunotherapy in acute myeloid leukemia." Cancer immunology, immunotherapy. 72, 10. 3323 - 3335. (2023).
https://digitalcommons.wustl.edu/oa_4/3127
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
